Individual approach to metastatic colorectal cancer treatment (clinical cases)

Two patients with metastatic colorectal cancer underwent R0 large bowel resection followed by surgery liver and lungs metastases, retroperitoneal lymph nodes and post-op chemotherapy. The total follow-up period of the first patient was currently 12 years, the recurrence-free period was 5 years. In the second patient, stabilization of the disease was observed for 12 years, and the total follow-up period – 18.5 years. An integrated treatment approach to metastatic CRC with active surgery for removable distant metastases or perioperative use of the most effective drug therapy for potentially resectable metastases can control the disease even with an aggressive course.

1. Kit O.I., Gevorkyan Yu.A., Soldatkina N.V., et al. Modern prognostic factors in colorectal cancer. Koloproktologia. 2021;20(2):42–49. (in Russ.). doi: 10.33878/2073-7556-2021-20-2-42-49

2. Kit O.I., Gevorkyan Yu.A., Soldatkina N.V., et al. Features of KRAS gene mutations in colorectal cancer in the south of Russia. Tyumen Medical Journal. 2015;17(3):20–22. eLibrary ID: 24850804. (in Russ.).

3. Vodolazhsky D.I., Antonets A.V., Dvadnenko K.V., et al. Connection of KRAS gene mutations with clinical and pathological features of colorectal cancer in patients of the South of Russia. International Journal of Experimental Education. 2014;1-1: 65-68. Available by: https://expeducation.ru/ru/article/view?id=4517 (accessed: 07/14/2023). (in Russ.).

4. Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2017;Feb 1;3(2):211–219. doi: 10.1001/jamaoncol.2016.4227

5. Xie MZ, Li JL, Cai ZM, et al. Impact of primary colorectal Cancer location on the KRAS status and its prognostic value. BMC Gastroenterol. 2019;Mar 27;19(1):46. doi: 10.1186/s12876-019-0965-5

6. Tie J, Desai J. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Target Oncol. 2015 Jun;10(2):179–88. doi: 10.1007/s11523-014-0330-0

7. Schmidt T, Nienhüser H, Kuna C, et al. Prognostic indicators lose their value with repeated resection of colorectal liver metastases. Eur J Surg Oncol. 2018 Oct;44(10):1610–1618. doi: 10.1016/j.ejso.2018.07.051

8. Carrato A, Abad A, Massuti B, et al.; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017 Aug;81:191–202. doi: 10.1016/j.ejca.2017.04.024

9. Modest DP, Denecke T, Pratschke J, et al. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. Eur J Cancer. 2018 Jan;88:77–86. doi: 10.1016/j.ejca.2017.10.028

10. Ciliberto D, Staropoli N, Caglioti F, et al. The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. Crit Rev Oncol Hematol. 2018 May;125:69–77. doi: 10.1016/j.critrevonc.2018.03.003

11. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004 Apr 1;22(7):1209–14. doi: 10.1200/JCO.2004.11.037

12. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1386–422. doi: 10.1093/annonc/mdw235